Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK reported core earnings of $1.09 per American depositary share (ADS) for second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow.

GSK expects both core operating profit and core EPS to grow in the range of 6-8% including the impact of the share buyback program. R&D is expected to increase at a rate similar to sales growth.